Rationale for Drug Development of Herbals in Oncology: Clinical, Industry, and Regulatory Perspectives

Eisenberg D, Davis R, Ettner S, et al. Trends in alternative medicine use in the United States, 1990–1997 results of a follow-up national survey. JAMA 1998;280:1569–1575.

Fisher P, Ward A. Complementary medicine in Europe. Br Med J 1994;309:107–111.

MacLennan AH, Wilson DH, Taylor AW. Prevalence and cost of alternative medicine in Australia. Lancet 1996;347:569–573.

Hauser SP. Unproven methods in cancer treatment. Curr Opinion Oncol 1993;5:646–654.

Eisenberg D, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: Prevalance, costs, and patterns of use. New Engl] Med 1993;328:246–252.

Cassileth BR, Lusk EF, Strouse TB, Bodenheimer BJ. Contemporary unorthodox treatments in cancer medicine: A study of patients, treatments, and practitioners. Ann Int Med 1984;101:105–112.

American Cancer Society. Unproven methods of cancer management—macrobiotic diets for the treatment of cancer. CA: A Cancer J Clinicians 1989;39(4):248–251.

Lerner IJ, Kennedy BJ. The prevalence of questionable methods of cancer treatments in the United States. Cancer 1992;42:181–191.

Richardson MA, Ramirez T, Nanney K, Singletary SE. Alternative/complementary medicine: implications for patient-provider communication. Proceedings of ASCO 1999;18:590A.

Gray RE, Fitch M, Greenberg M, et al. Perspectives of cancer survivors interested in unconventional therapies. J Psychosocial Oncology 1997;15:149–171.

Burstein HJ, Gelber S, Guadagnoli E, Weeks JC. The use of complementary health strategies by women with early stage breast cancer. Presented at the American Cancer Society Meeting, 1998.

Coppes MJ, Anderson RA, Egeler RM, Wolff JEA. Alternative therapies for the treatment of childhood cancer. New Engl J Med 1998;339:846–847.

Wetzel MS, Eisenberg DM, Kaptchuk TJ. Courses involving complementary and alternative medicine at US medical schools. JAMA 1998;280:784–787.

Astin JA. Why patients use alternative medicine. Results of a national study. JAMA 1998;279:1548–1553.

Hoey J. The arrogance of science and the pitfalls of hope. (Editorial). Canadian Med Assoc J 1998;159:803–804.

Durant JR. Alternative medicine: an attractive nuisance. (editorial). J Clinical Oncology 1998;16:1–2.

Tannock IF, Warr DG. Unconventional therapies for cancer: a refuge from the rules of evidence? Canadian Med Assoc J. 1998;159:801–802.

Office of Alternative Medicine. Washington, DC: First Investigators Meeting; 1994.

Cooper RA, Stoflet SJ. Trends in the education and practice of alternative medicine clinicians. Health Aff. (Millwood) 1996;15:226–238.

Ernst E, Resch K, White AR. Complementary medicine: what physicians think of it—a meta-analysis. Arch Intern Med 1995;155:2405–2408.

Spiegel D, Stroud P, Fyfe A. Complementary medicines. Wes J Med 1998;168:241–247.

Bourgeault I. Physicians’ attitudes toward patients’ use of alternative cancer therapies. Can Med Assoc J 1996;155(12):1679–1685.

Angell M, Kassirer P. Alternative medicine—the risks of untested and unregulated remedies. New Engl J Med 1998;339:839–841.

DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. New Engl J Med 1998;339:785–791.

Bailar JC, Gornik HL. Cancer undefeated. New Engl J Med 1997;336(33):1569–1574.

Bussing A. Mistletoe therapy and immunological research. Anti-Cancer Drugs (Suppl) 1997;8:S65.

Gabius HJ, Andre S, Kaltner J, Siebert HC, von der Lieth CW, Gabius S. The mistletoe myth: claims, reality and provable perspectives. Zeitschrift Fur Arztliche Fortbildung 1996;90:103–110.

Hajto T, Hostanska K, Gabius HJ. Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 1989;49:4803–4808.

Hajto T, Hostanska K, Frei K, Rordorf C, Gabius HJ. Increased secretion of tumor necrosis factor alpha, Interleukin 1, and Interleukin 6 by human mononuclear cells exposed to b-Galactoside-specific Lectin from clinically applied mistletoe extract. Cancer Res 1990;50:3322–3326.

Douwes FR, Wolfram DI, Migeod F. Results of a prospective randomized study on chemotherapy vs. chemotherapy plus biological response modifier in metastasizing colorectal carcinoma. Krebsgeschehen 1986;18:155–164.

Douwes FR, Kalden M, Frank G, Holzhauer P. Treatment of advanced colorectal carcinoma. Onkologie. 1988.

Boie D, Gutsch J. Helixor in cancer of colon and rectum. Schriftenreihe Krebsgeschehen 1980;23:65–76.

Gutsch J, Berger H, Scholz G, Denck H. Prospective study in radically operated breast cancer with polychemotherapy, Helixor and untreated control. Deutsche Zeitschrift Fur Onkologie 1988;21:94–101.

Warner-Lambert. Warner-Lambert launches quanterra (TM): standardized herbal supplements clinically proven by doctors to be safe and effective— quanterra mental sharpness with ginko biloba and quanterra prostate, with saw palmetto. NewsEdge Corp./Newswire. October 14, 1998.

The University of Texas—Houston Center for Alternative Medicine, http://www.sph.tmc.edu/utcam/.

Houghton PJ. Establishing identification criteria for botanicals. Drug Inf J 1998;32:461–469.

Lazarowych N, Pekos P. Use of fingerprinting and marker compounds for identification and standardization of botanical drugs: strategies for applying pharmaceutical HPL. analysis to herbal products. Drug Inf J 1998;32:497–512.

Eskinazi DP. Factors that shape alternative medicine. JAMA 1998;280(18):1621–1623.